Segment & Geographic Data Quant-Grade Normalized (live API) API & CSV Delivery

Anteris Technologies Global's Business Segments

Anteris Technologies Global's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.

Segment Data As of Q1 FY2026

Reportable Segments

Per the company's own filing, this quarter

Largest Segment

Anteris Business Segment

100% of revenue

Total Revenue

$ 0

Consolidated, this quarter

Countrys Reported

Geographic countrys, this quarter

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/AVR/segments                    

                        https://api.csimarket.com/api/v1/companies/AVR/geographic                    

                        https://api.csimarket.com/api/v1/companies/AVR/exposure                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Revenue Share by Reportable Segment - Q1 FY2026

Anteris Business Segment100%

Revenue by Reportable Segment - Q1 FY2026

Segment	Period	Revenue (Millions)	% of Total	Operating Income
Anteris Business Segment	Q1 FY2026	$ 0	100%	-

Revenue Share by Country - Q1 FY2026

US98%
AU2%

Revenue by Geographic Country - Q1 FY2026

Country	Period	Revenue (Millions)	% of Total
US	Q1 FY2026	$ 0	98%
AU	Q1 FY2026	$ 0	2%

Description of Anteris Technologies Global

Anteris Technologies Global Corp. is a medical technology company specializing in the development and commercialization of transcatheter heart valve (THV) products for treating aortic stenosis. Its primary product, the DurAVR® THV, is a biomimetic valve constructed from a single piece of native-shaped ADAPT® anti-calcification tissue derived from bovine heart tissue through the ADAPT® tissue engineering process. The DurAVR® THV is designed to replicate human tissue and is implanted via a minimally invasive transcatheter aortic valve replacement (TAVR) procedure, which places the new valve inside the diseased valve without removal. The company also developed the ComASUR® Delivery System, a balloon-expandable device that allows controlled deployment and precise placement of the DurAVR® THV, aligning the valve leaflets with the native valve commissures. Anteris’s technology aims to improve hemodynamics, reduce valve wear, and enhance patient outcomes by maintaining laminar blood flow and minimizing turbulence. The company underwent a reorganization prior to its initial public offering in December 2024, operating as Anteris Technologies Pty Ltd before the reorganization and as Anteris Technologies Global Corp. thereafter.

Management has identified a single business segment based on the review by the chief operating decision maker (CODM). This segment involves the development and commercialization of the ADAPT® anti-calcification tissue, specifically focused on the DurAVR® THV System.